TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Core Insights - TG Therapeutics, Inc. announced the schedule for presentations on BRIUMVI (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis (RMS) at the 2025 ECTRIMS annual meeting in Barcelona, Spain [1][2] Presentation Details - An oral presentation will cover the long-term efficacy and safety of ublituximab based on six years of data from the ULTIMATE I and II open-label extension studies [2] - ePoster presentations will include updates on a modified dosing regimen from the ENHANCE study and real-world clinical experiences from the ENABLE Phase 4 observational study [2] Clinical Trials Overview - The ULTIMATE I & II trials are randomized, double-blind, and active comparator-controlled studies involving 1,094 patients with RMS across 10 countries, treated for 96 weeks [3] - Patients were randomized to receive either BRIUMVI or teriflunomide, with specific dosing regimens outlined for both treatments [3] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to enhance B-cell depletion at lower doses through glycoengineering [4][5] - It is approved in the U.S. and Europe for treating adults with RMS, including various forms of the disease [5][26] Safety and Efficacy Data - The incidence of infusion reactions in BRIUMVI-treated patients was reported at 48%, with serious reactions occurring in 0.6% of patients [7] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [9] Company Background - TG Therapeutics is focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI being a key product in their portfolio [26]